Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)-Reference-Cited by-同舟云学术

Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)

Published:2018-11-06 Issue:1 Volume:18 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Rinnerthaler Gabriel,Gampenrieder Simon Peter,Petzer Andreas,Burgstaller Sonja,Fuchs David,Rossmann Dieter,Balic Marija,Egle Daniel,Rumpold Holger,Singer Christian F.,Bartsch Rupert,Petru Edgar,Melchardt Thomas,Ulmer Hanno,Mlineritsch Brigitte,Greil Richard

Funder

Takeda Pharmaceuticals U.S.A.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-018-4979-0.pdf

Reference48 articles.

1. Global Burden of Disease Cancer C, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 To 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3(4):524–48.

2. Corona SP, Sobhani N, Ianza A, Roviello G, Mustacchi G, Bortul M, Zanconati F, Generali D. Advances in systemic therapy for metastatic breast cancer: future perspectives. Med Oncol. 2017;34(7):119.

3. Robertson L, Hanson H, Seal S, Warren-Perry M, Hughes D, Howell I, Turnbull C, Houlston R, Shanley S, Butler S, et al. BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br J Cancer. 2012;106(6):1234–8.